Biostimulant Manufacturing Patents: Leaders, Trends & White Space 2026
- Filing activity peaked in 2020 at 18 families and has since flattened, with the 2022 midpoint at 11 — a plateau rather than a growth curve, though the most recent years are still filling in as publications lag filing.
- A01N and C05F dominate the IPC mix (54 and 51 of 76 records), while C12N microbial engineering and C05G fertiliser mixtures sit far behind — the formulation side of the process is far more claimed than the strain-engineering side.
- The most-cited record, EP0298136A1, carries 46 citations, roughly three times the next most-cited family — an unusually concentrated citation base that points to one foundational formulation patent shaping everything downstream.
Filing growth compares 2021 (2 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 76 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 76 patent families published between 2015 and mid-2026 that combine biostimulant terminology with process-specific language — fermentation production, stabilized formulation, extraction — filed under IPC classes covering agrochemicals, organic fertilisers and microorganism-related subject matter. It is scoped to how biostimulant products are made, not to the biological claims about what a biostimulant does once applied.
The set spans classical organomineral fertiliser processing through to microbial strain formulations and marine-plant extraction routes, giving a cross-section of the manufacturing side of a market that is otherwise dominated by efficacy and application claims.
Filing trend and technology composition
Two views of the same 76-family dataset: when the filings happened, and which parts of the International Patent Classification they sit in.
Filings plateaued after a 2020 peak
Activity rose from 2 families in 2017 to a peak of 18 in 2020, then eased back toward the 2022 midpoint of 11 — a flat-to-declining pattern rather than sustained growth. Because publication trails filing by around 18 months, the 2025-2026 figures will revise upward as later applications publish, but the plateau shape through 2022-2023 is already established.
Agrochemical and fertiliser classes dominate
A01N (54 records) and C05F (51) between them cover the great majority of the dataset, with A01P pesticide-activity claims close behind at 39. Microorganism-specific classes — C12N and C12R — appear in only 16 and 15 records respectively, and fertiliser-mixture class C05G in just 11, suggesting the manufacturing claim space is weighted toward formulation and stabilisation rather than microbial strain engineering or blended-fertiliser process claims.
Shares are the percentage of the 76 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Agricultural Biostimulant Manufacturing Process with Eureka
This page is one run against one query. Ask Eureka your own question about agricultural biostimulant manufacturing process and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping this space
Method for producing plant biostimulant from marine plants (US20240298650A1)
Disclosed herein are methods for producing a plant biostimulant from marine plants. In one aspect, the present disclosure provides a biostimulant product produced by a novel and nonobvious process. In yet another aspect the biostimulant increases crop yields, fruit production, flower sets, and plant size. Biostimulant is an organic, non-toxic product that increases plant growth and invigorates plants. The plant biostimulant is produced from marine plants including but not limited to various types of seaweed.Filed by ABDUL-AKBAR, TARIQ, published 2024-09-12 — one of the more recent process-specific filings in the dataset, illustrating the marine-extraction route alongside the microbial and organomineral routes.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | EP0298136A1 | Universal organomineral and biostimulating fertilizer and a method for the manufacture thereof | 46 |
| 2 | WO2019155252A1 | Novel bacillus SP. simplex and uses thereof | 15 |
| 3 | WO2019155253A1 | Novel paenibacillus polymyxa and uses thereof | 14 |
| 4 | WO2020245675A1 | Methylobacterium sp. nov. strain, compositions comprising it, and its use as BIO-stimulant and endophyte nitr… | 10 |
| 5 | US20210276927A1 | Novel paenibacillus polymyxa and uses thereof | 9 |
| 6 | US20220242800A1 | Composition and method for improving plant growth | 8 |
| 7 | WO2023009636A1 | Bionutritional compositions for plants and soils | 6 |
| 8 | WO2021094552A1 | Sunflower bark extract and uses thereof | 6 |
| 9 | US20230000089A1 | Composition enriched in polyphenols and flavonoids for use as biostimulant and antimicrobial for agriculture … | 4 |
| 10 | WO2020107116A1 | Process for the manufacture of a biostimulant or natural fertilizer based on fermented macroalgae, natural ad… | 4 |
Citation counts are pulled from within the searched corpus and favour older filings; treat them as a measure of influence on later applicants, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about this field
Reading the filing trend, IPC composition and citation pattern together points to a manufacturing space that is claim-dense in formulation but comparatively open in strain engineering and blended-fertiliser processing.
One foundational formulation patent anchors the field
EP0298136A1's citation count is roughly three times that of the next most-cited family, meaning most later organomineral and biostimulant formulation filings trace back to a single early reference point rather than several competing lineages.
Formulation and biocidal activity classes crowd the top
The three largest IPC classes all relate to agrochemical or fertiliser formulation and activity, not to microbial strain construction — a sign that process claims cluster around stabilising and delivering an active ingredient rather than engineering the organism itself.
Growth has flattened since the 2020 peak
Filings rose steadily to 2020 then eased back toward the 2022 midpoint of 11, a plateau that predates the most recent, still-incomplete years. New entrants filing manufacturing-process claims now are filing into a space with an established prior-art base rather than a fast-growing one.
Filing activity is spread across offices, not concentrated in one
The United States, EPO and WIPO/PCT each account for a similar share of receiving-office activity, with India, Australia and Israel each in the mid-single digits — indicative of a genuinely international filing strategy rather than a single home-market focus.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to agricultural biostimulant manufacturing process, with the prior art for and against each one.
Who is filing, and where the activity has cooled
Co-assignee pairings show university-industry collaboration clusters, but recent-year momentum across the named assignees points to a field where the leading filers have gone quiet rather than accelerated.
University partnerships anchor the strongest collaborations
Ghent University and the Catholic University of Leuven co-file together on 6 records, and each also pairs with Toulouse INP on 4 — a triangle of academic co-assignment that is the densest collaboration pattern in the dataset.
Named leaders show no filings in the most recent year
Every assignee tracked for year-over-year momentum, including the entity with a -100% YoY change, shows zero filings in the latest year. That is consistent with the broader plateau in the trend data, though the newest filings are also the ones most likely to still be unpublished.
A long tail behind a small set of repeat filers
With 76 families spread across dozens of named assignees and a concentrated citation base sitting on one early formulation patent, the field looks more like a long tail of single- or few-filing entrants than a market with an entrenched multi-filer leader.
| Assignee | Recent year | YoY |
|---|---|---|
| Agrivert S.A. | 0 | -100% |
| Symborg S.L. | 0 | — |
| Valagro S.p.A. | 0 | — |
| Ghent University | 0 | — |
| Envirocore Inc. | 0 | — |
| Catholic University of Leuven (KU Leuven) | 0 | — |
| PROD BIO SUN INC | 0 | — |
| Unifeerx International Ltd. | 0 | — |
Where to take this analysis
The dataset points to specific next questions for anyone drafting into this space or scouting for freedom to operate.
Map the formulation prior art around EP0298136A1
Given its outsized citation count, any new organomineral or biostimulant formulation filing should be checked against this family and its citing documents before drafting claims.
Explore citation trees in EurekaStress-test claims in the under-claimed branches
C05G blended-fertiliser processing and microbial strain stabilisation both carry thinner IPC coverage than the core A01N/C05F classes — worth a freedom-to-operate pass before committing R&D spend.
Run a white space search in EurekaWatch for republished filings from quiet assignees
Zero recent-year filings across the named leading assignees may reflect the publication lag rather than an actual pullback; re-check momentum once 2025-2026 data matures.
Track assignee activity in EurekaCommon questions about this landscape
In this landscape it means a patent family that combines biostimulant subject matter with process-specific language such as fermentation production, stabilized formulation, or extraction, filed under IPC classes covering agrochemicals (A01N), organic and waste-derived fertilisers (C05F), or microorganism-related subject matter (C12P, C12N, C12R). It excludes filings that only claim the biological effect of applying a biostimulant without describing how the product is made. This scoping is what separates a manufacturing-process landscape from a broader biostimulant efficacy landscape covering the same market.
The dataset's assignee ranking (rendered in the table above) is a long tail: no single company or institution dominates filing volume, and the strongest collaboration pattern is academic rather than industrial, with Ghent University, the Catholic University of Leuven and Toulouse INP appearing together across several co-assigned families. Several named assignees show zero filings in the most recent tracked year, though that partly reflects the roughly 18-month lag between filing and publication rather than firms exiting the space. Anyone scouting for an acquisition target or licensing partner should check the full ranking table rather than assume one obvious leader.
The data shows filings rising to a peak of 18 in 2020 before easing back to 11 by the 2022 midpoint, a plateau rather than a decline driven by any single cause visible in this dataset. It is consistent with a wave of formulation and process patents following growing regulatory recognition of biostimulants as a distinct product category in several jurisdictions around that period. The evidence here does not include regulatory filings, so this should be read as a filing-volume observation, not a causal claim about specific policy events.
IPC composition points to microbial strain stabilisation, blended organomineral-fertiliser processing (C05G), and inorganic carrier formulation (C05D) as comparatively thin relative to the dominant A01N and C05F classes, which together cover the large majority of the 76 tracked families. Marine and algal extraction processes, illustrated by the representative US20240298650A1 filing, also sit outside the densest citation clusters. These are not guarantees of a clean filing, but they carry less occupied claim space than the core formulation classes.
Citation counts here are drawn from within the searched corpus itself, and that structurally favours older filings simply because they have had more time to be cited by later applicants. EP0298136A1's 46 citations make it the clear historical anchor of the formulation sub-space, but a low citation count on a 2023 or 2024 filing does not mean it is unimportant — it may simply be too recent to have accumulated citations yet. Use citation rank as a signal of past influence, and use the filing trend and IPC composition to judge where current activity is concentrated.
Research Agricultural Biostimulant Manufacturing Process in depth with Eureka
Go past this page: query the whole agricultural biostimulant manufacturing process corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.